英诺特: 北京市中伦律师事务所关于北京英诺特生物技术股份有限公司2024年年度股东大会的法律意见书

Core Viewpoint - The legal opinion confirms the legitimacy of the 2024 annual general meeting of Beijing Innotech Biotechnology Co., Ltd., ensuring compliance with relevant laws and regulations [1][11]. Group 1: Meeting Procedures - The notice for the 2024 annual general meeting was properly issued, detailing the time, location, agenda, and registration methods for shareholders [3][4]. - The meeting was held at the specified location and was presided over by the chairman, Ye Fengguang [4][5]. Group 2: Attendance and Qualifications - A total of 7 shareholders attended the meeting in person, representing 68,709,082 shares, which is a significant portion of the voting rights [6]. - 57 shareholders participated in the online voting, with their qualifications verified by the Shanghai Stock Exchange [6][11]. Group 3: Voting Procedures and Results - The meeting utilized both on-site and online voting methods, with results being monitored and counted by designated personnel [7][11]. - Various resolutions were passed with overwhelming support, including votes where over 99% of the attending shareholders approved the proposals [7][10].